Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This phase 1/2 trial addresses the efficacy and safety of the combination of dabrafenib,
trametinib and the oral autophagy inhibitor hydroxychloroquine in patients with unresectable
AJCC (American Joint Committee on Cancer) stage III or stage IV BRAF (v-Raf murine sarcoma
viral oncogene homolog B) V600 mutant melanoma who are documented with progression of disease
following treatment with a BRAF with or without MEK (MAPK/Erk kinase) inhibitor and treatment
with an immune checkpoint inhibitor. The investigators hypothesize hydroxychloroquine will be
able to overcome or prevent autophagy-driven resistance to dabrafenib and trametinib. The
investigators will also investigate the value of plasma BRAF V600 mutant circulating tumor
DNA (ctDNA) as a predictive or prognostic marker.